Neuralace Medical Announces Clinical Milestones Including Presentation of the Safety and Efficacy of Axon Therapy (SEAT) Study at the American Society of Pain and Neuroscience Conference (ASPN), While Completing Enrollment in the Axon Therapy Painful Diabetic Neuropathy Study (AT-PDN) and Launching a Pilot Study Focused on the Treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN)
Neuralace Medical will continue to leverage clinical milestone progress to support its current seed fundraising efforts highlighted by a recent first close of $3.1M targeting a total raise of $5-$7M